Literature DB >> 21972848

Factor VIII deficiency does not protect against atherosclerosis.

Sara Biere-Rafi1, A Tuinenburg, B W Haak, M Peters, R Huijgen, E De Groot, P Verhamme, K Peerlinck, F L J Visseren, M J H A Kruip, B A P Laros-Van Gorkom, V E A Gerdes, H R Buller, R E G Schutgens, P W Kamphuisen.   

Abstract

BACKGROUND: Hemophilia A patients have a lower cardiovascular mortality rate than the general population. Whether this protection is caused by hypocoagulability or decreased atherogenesis is unclear.
OBJECTIVES: To evaluate atherosclerosis and endothelial function in hemophilia A patients with and without obesity as well as in matched, unaffected controls.
METHODS: Fifty-one obese (body mass index [BMI] ≥ 30 kg m(-2)) and 47 non-obese (BMI ≤ 25 kg m(-2)) hemophilia A patients, and 42 obese and 50 matched non-obese male controls were included. Carotid and femoral intima–media thickness [IMT] and brachial flow-mediated dilatation (FMD) were measured as markers of atherogenesis and endothelial function.
RESULTS: The overall population age was 50 ± 13 years. Carotid IMT was increased in obese subjects (0.77 ± 0.22 mm) as compared with non-obese subjects (0.69 ± 0.16 mm) [mean difference 0.07 mm (95% confidence interval [CI] 0.02–0.13, P = 0.008)]. No differences in mean carotid and femoral IMT between obese hemophilic patients and obese controls were found (mean difference of 0.02 mm [95% CI ) 0.07–0.11, P = 0.67], and mean difference of 0.06 mm [95% CI ) 0.13–0.25, P = 0.55], respectively). Thirty-five per cent of the obese hemophilic patients and 29% of the obese controls had an atherosclerotic plaque (P = 0.49), irrespective of the severity of hemophilia. Brachial FMD was comparable between obese hemophilic patients and obese controls (4.84% ± 3.24% and 5.32% ± 2.37%, P = 0.45).
CONCLUSION: Hemophilia A patients with obesity develop atherosclerosis to a similar extent as the general male population. Detection and treatment of cardiovascular risk factors in hemophilic patients is equally necessary.

Entities:  

Mesh:

Year:  2012        PMID: 21972848     DOI: 10.1111/j.1538-7836.2011.04499.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  14 in total

1.  Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

Authors:  R H Olie; P E J van der Meijden; H M H Spronk; H Ten Cate
Journal:  Handb Exp Pharmacol       Date:  2022

Review 2.  Acute coronary syndrome in patients with hemophilia: a delicate balancing act.

Authors:  Jacob J Mayfield; Andrew D Leavitt; Talha Tanriverdi; Krishan Soni; Thomas A Ports; M Roselle Abraham
Journal:  J Thromb Thrombolysis       Date:  2022-05-11       Impact factor: 5.221

Review 3.  Management of Hemophilia in Older Patients.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

4.  Risk factors for cardiovascular disease in children and young adults with haemophilia.

Authors:  Jacqueline Limjoco; Courtney D Thornburg
Journal:  Haemophilia       Date:  2018-07-13       Impact factor: 4.287

5.  A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Authors:  Suman L Sood; Dunlei Cheng; Margaret Ragni; Craig M Kessler; Doris Quon; Amy D Shapiro; Nigel S Key; Marilyn J Manco-Johnson; Adam Cuker; Christine Kempton; Tzu-Fei Wang; M Elaine Eyster; Philip Kuriakose; Annette von Drygalski; Joan Cox Gill; Allison Wheeler; Peter Kouides; Miguel A Escobar; Cindy Leissinger; Sarah Galdzicka; Marshall Corson; Crystal Watson; Barbara A Konkle
Journal:  Blood Adv       Date:  2018-06-12

Review 6.  Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.

Authors:  Victor A Ferraris; Leonard I Boral; Alice J Cohen; Susan S Smyth; Gilbert C White
Journal:  Cardiol Rev       Date:  2015 Mar-Apr       Impact factor: 2.644

7.  Carotid plaque is a new risk factor for peripheral vestibular disorder: a retrospective cohort study.

Authors:  Masaoki Wada; Taro Takeshima; Yosikazu Nakamura; Shoichiro Nagasaka; Toyomi Kamesaki; Eiji Kajii
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 8.  Comorbidities of cardiovascular disease and cancer in hemophilia patients.

Authors:  Jiaan-Der Wang
Journal:  Thromb J       Date:  2016-10-04

9.  The coagulation system in atherothrombosis: Implications for new therapeutic strategies.

Authors:  Renske H Olie; Paola E J van der Meijden; Hugo Ten Cate
Journal:  Res Pract Thromb Haemost       Date:  2018-02-19

10.  Cardiac surgery in patients with Hemophilia:is it safe?

Authors:  Amjad Shalabi; Erez Kachel; Alexander Kogan; Leonid Sternik; Liza Grosman-Rimon; Ronny Ben-Avi; Diab Ghanem; Eilon Ram; Ehud Raanani; Mudi Misgav
Journal:  J Cardiothorac Surg       Date:  2020-05-08       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.